Focus on Coronavirus Disease 2019 Associated Coagulopathy
The coronavirus disease 2019 (COVID-19) has emerged as a global pandemic, posing significant challenges to public health systems worldwide. Among the myriad complications associated with COVID-19, coagulopathy has been identified as a critical factor influencing disease severity and patient prognosis. Understanding the prevalence, underlying mechanisms, and clinical implications of COVID-19-associated coagulopathy is essential for effective diagnosis and management.
Prevalence and Characteristics of Coagulopathy in COVID-19
COVID-19 patients frequently exhibit coagulation abnormalities, ranging from mild parameter deviations to severe disseminated intravascular coagulation (DIC). The most common coagulation abnormality observed in COVID-19 patients is the elevation of D-dimer, a marker of fibrin degradation. Studies have reported that elevated D-dimer levels are present in 36% to 46.4% of COVID-19 cases. The degree and persistence of D-dimer elevation are strong predictors of poor prognosis. For instance, a study involving 183 confirmed COVID-19 cases (21 deaths, 162 survivors) from Wuhan Tongji Hospital revealed that non-survivors had significantly higher D-dimer levels compared to survivors (2.12 mg/mL vs. 0.61 mg/mL, P < 0.001). Furthermore, a multivariable logistic regression model based on 191 patients (54 non-survivors, 137 survivors) indicated that a D-dimer level greater than 1.0 mg/mL at admission was associated with an 18.42-fold increased risk of mortality.
In contrast to severe acute respiratory syndrome (SARS), changes in activated partial thromboplastin time (APTT) and prothrombin time (PT) in COVID-19 patients are inconsistent. One study found that 16% and 30% of patients exhibited shortened APTT and PT, respectively, while 6% and 5% showed prolonged APTT and PT. Another study reported that 50% of non-survivors exhibited coagulopathy, characterized by a 3-second increase in PT or a 5-second increase in APTT. A meta-analysis confirmed that PT and D-dimer levels were significantly higher in severe COVID-19 patients compared to mild cases, although no significant differences in platelet count (PLT) and APTT values were observed between the two groups.
Thrombocytopenia is less frequently observed in COVID-19 patients compared to SARS patients. A meta-analysis of nine studies found that platelet counts were significantly lower in severe COVID-19 patients compared to mild cases, with a mean difference of 31 × 10^9/L.
Incidence and Implications of Disseminated Intravascular Coagulation (DIC)
The incidence of DIC in COVID-19 patients varies across studies. Among 1,099 COVID-19 patients, only one case (0.1%) was diagnosed with DIC. However, another study reported a higher DIC incidence rate in the death group (6.4%) compared to survivors (0%). A study by Tang et al. found an overall DIC incidence rate of 8.74%, with 71.4% of non-survivors meeting the International Society of Thrombosis and Hemostasis (ISTH) diagnostic criteria for DIC, compared to only 0.6% of survivors.
Etiology and Pathogenesis of COVID-19 Associated Coagulopathy
The exact etiology and pathogenesis of COVID-19-associated coagulopathy remain unclear. However, several factors are believed to contribute to coagulation dysfunction in COVID-19 patients. These include direct viral attack by the 2019 novel coronavirus (2019-nCoV), cytokine storm-mediated inflammation-coagulation cascades, hypoxia, and endothelial dysfunction.
Postmortem studies have demonstrated viral entry into endothelial cells, leading to inflammatory cell infiltration, cytokine storm, endothelial cell apoptosis, and microvascular prothrombosis, ultimately resulting in DIC. Interleukin-6 levels have been shown to positively correlate with fibrinogen levels, highlighting the link between inflammation and procoagulant changes. Hypoxia, a hallmark of severe COVID-19, activates hypoxia-induced factors in type II alveolar epithelial cells, stimulating coagulation cascades and thrombosis formation, which in turn exacerbates hypoxia and lung injury.
Diagnostic Criteria for COVID-19 Associated Coagulopathy
Currently, there are no standardized criteria to define COVID-19-associated coagulopathy. Typically, it reflects abnormalities in coagulation tests without meeting the classic criteria for clinical coagulopathy, which involves impaired clotting ability leading to bleeding. Suggested diagnostic criteria include a platelet count (PLT) below 100 × 10^9/L, a reduction in PT and APTT beyond the lower limit of the 99th percentile, an increase in PT by more than 3 seconds, or an increase in APTT by more than 5 seconds. Additionally, elevated fibrinogen, fibrin degradation product (FDP), and D-dimer levels beyond the 99th percentile, in the absence of primary blood system diseases or chronic liver diseases, are indicative of COVID-19-associated coagulopathy.
The ISTH scoring system is recommended for diagnosing DIC, with an ISTH score of 5 or higher indicating overt-DIC. Given the association between elevated D-dimer levels at admission and increased mortality, as well as the correlation between rising D-dimer and PT, rapid decreases in fibrinogen and platelet counts, and the development of overt-DIC and multiorgan failure, hospitalized COVID-19 patients should undergo coagulation testing upon admission and throughout their hospital stay. Essential tests include D-dimer, PT, APTT, fibrinogen, and platelet count.
Clinical Manifestations and Venous Thromboembolism (VTE) Risk
COVID-19-associated coagulopathy often lacks overt clinical manifestations. The most common clinical feature is thrombosis in the deep veins or intermuscular veins of the lower extremities, which can be identified through coagulation parameters and ultrasound monitoring. COVID-19 patients are at high risk of venous thromboembolism (VTE) due to hypercoagulability, prolonged immobilization, dehydration, advanced age, and comorbidities such as hypertension, diabetes, obesity, and cardiovascular disease. Reports indicate that up to 31% of severe COVID-19 patients admitted to the intensive care unit (ICU) develop VTE or thrombotic complications, with a D-dimer level above 1.5 mg/mL serving as a reliable indicator for identifying high-risk patients.
Management and Treatment Strategies
Given the high risk of VTE in COVID-19 patients, it is crucial to assess VTE risk in all hospitalized patients. For severe or critically ill patients, as well as mild or moderate cases with a high VTE risk, early pharmacological thromboprophylaxis with low molecular weight heparin (LMWH) is recommended, provided there are no contraindications. In patients with a high bleeding risk, intermittent pneumatic compression is advised for mechanical prevention.
Autopsy findings of extensive microthrombosis in alveolar, myocardial, and renal tubular epithelial cells suggest that anticoagulation therapy may benefit COVID-19 patients. LMWH or unfractionated heparin are preferred due to their anti-inflammatory properties. However, the optimal dose of anticoagulation therapy remains controversial. Some studies suggest that prophylaxis doses of LMWH are associated with better prognosis in severe COVID-19 patients with a sepsis-induced coagulopathy (SIC) score of 4 or higher or a D-dimer level more than six times the normal upper limit. A Delphi consensus document indicated that 31.6% of participants supported intermediate-intensity doses, 5.2% supported therapeutic doses, and the majority favored standard VTE prophylaxis doses for hospitalized patients with moderate to severe COVID-19 without DIC. A risk-adapted strategy, escalating prophylaxis or therapeutic doses based on D-dimer levels, SIC score, ICU admission, VTE complications, and other indications, is recommended. Further randomized controlled studies are needed to determine the appropriate dose and timing of anticoagulation treatment for COVID-19-associated coagulopathy. Caution is advised when using LMWH in patients with renal insufficiency due to its longer half-life. For patients at high risk of bleeding, anticoagulation is not recommended, and traditional Chinese medicine promoting blood circulation may be considered.
Concurrent DIC and Management Considerations
Concurrent DIC is a strong predictor of mortality in COVID-19 patients. Treatment strategies should focus on addressing the underlying pathology, including antiviral therapy and organ function support. Although bleeding manifestations are uncommon in COVID-19-associated coagulopathy, thrombosis and bleeding may occur simultaneously in the late stages of overt-DIC, necessitating a balance between anticoagulation and bleeding risk. If bleeding develops, treatment principles similar to those for septic coagulopathy, as outlined in the ISTH interim guidance, should be followed. Blood products and coagulation factor replacement should be administered to maintain a platelet count above 50 × 10^9/L, fibrinogen above 1.5 g/L, and a PT ratio below 1.5. Experimental therapies, such as recombinant human thrombomodulin and antithrombin, may also be considered.
Given the role of cytokine storm in the development of COVID-19-associated coagulopathy, blood purification techniques may be beneficial in severely and critically ill patients to mitigate cytokine storm and improve prognosis.
Conclusion
Coagulopathy is a significant contributor to the rapid progression and poor prognosis of COVID-19 patients. Close monitoring of coagulation indicators, routine screening for VTE risk, and appropriate anticoagulation treatment are essential components of COVID-19 management. An algorithm for the management of COVID-19-associated coagulopathy has been proposed, emphasizing the importance of early diagnosis and intervention. Continued research and clinical studies are necessary to refine treatment strategies and improve patient outcomes.
doi.org/10.1097/CM9.0000000000001019
Was this helpful?
0 / 0